GBD 2021 Sickle Cell Disease Collaborators, ThomsonAM, McHughTA, et al.Global, regional, and national prevalence, and mortality burden of sickle cell disease, 2000–2021: A systematic analysis from the Global Burden of Disease Study 2021. Lancet Haematol, 2023; 10(8):e585–e599; doi: 10.1016/s2352-3026(23)00118-7
3.
AtagaKI, KutlarA, KanterJ, et al.Crizanlizumab for the prevention of pain crises in sickle cell disease. N Engl J Med, 2016:NEJMoa1611770; doi: 10.1056/nejmoa1611770
4.
PeckerLH, EllsworthP. Raise the roof, build the floor. Blood, 2022; 140(13):1453–1455; doi: 10.1182/blood.2022017213
5.
PeckerLH, SharmaD, NeroA, et al.Knowledge gaps in reproductive and sexual health in girls and women with sickle cell disease. Br J Haematol, 2021; 194(6):970–979; doi: 10.1111/bjh.17658
6.
CampbellJ, et al.Pain frequency and healthcare utilization patterns in women with sickle cell disease experiencing menstruation associated crisis: A CASiRe Analysis. J Women's Health (Larchmt), 2023.
7.
SmithWR, PenberthyLT, BovbjergVE, et al.Daily assessment of pain in adults with sickle cell disease. Ann Intern Med, 2008; 148(2):94; doi: 10.7326/0003-4819-148-2-200801150-00004
8.
SavittTL, SmithWR, HaywoodC, et al.Use of the word “Crisis” in sickle cell disease: The language of sickle cell. J Natl Méd Assoc, 2014; 106(1):23–30; doi: 10.1016/s0027-9684(15)30067-5
9.
BrandowAM, CarrollCP, CrearyS, et al.American Society of Hematology 2020 guidelines for sickle cell disease: Management of acute and chronic pain. Blood Adv, 2020; 4(12):2656–2701; doi: 10.1182/bloodadvances.2020001851
10.
LintonEA, WilliamsEC, EarlyML, et al.Family planning needs of young adults with sickle cell disease. eJHaem, 2023; doi: 10.1002/jha2.711
11.
KhachikyanI, Speller-BrownB, Gomez-LoboV, et al.Reproductive health, and knowledge among youth with sickle cell disease. J Nurse Pract, 2022; 18(7):726–729; doi: 10.1016/j.nurpra.2022.04.016
12.
DayM, BonnetK, SchlundtDG, et al.Vaso-occlusive pain, and menstruation in sickle cell disease: A focus group analysis. Women's Health Rep, 2020; 1(1):36–46; doi: 10.1089/whr.2019.0008
13.
SharmaD, DayME, StimpsonSJ, et al.Acute vaso-occlusive pain is temporally associated with the onset of menstruation in women with sickle cell disease. J Women's Health (Larchmt) (2002), 2019; 28(2):162–169; doi: 10.1089/jwh.2018.7147
14.
KarafinMS, SinghM, CeesayM, et al.Dyspareunia is associated with chronic pain in premenopausal women with sickle cell disease. Hematology, 2018; 23(8):531–536; doi: 10.1080/10245332.2018.1430521
15.
AdesoyeOB, AkhigbeRE. Predictors of sex-induced crisis, sexual function and marital satisfaction in women with sickle cell disease. J Sex Med, 2022; 19(11):1625–1633; doi: 10.1016/j.jsxm.2022.07.013
16.
PeckerLH, MaherJY, LawJY, et al.Risks associated with fertility preservation for women with sickle cell anemia. Fertil Steril, 2018; 110(4):720–731; doi: 10.1016/j.fertnstert.2018.05.016
17.
AsareEV, DeBaunMR, OlayemiE, et al.Acute pain episodes, acute chest syndrome, and pulmonary thromboembolism in pregnancy. Hematology, 2022; 2022(1):388–407; doi: 10.1182/hematology.2022000376
18.
QueirozAM, Lobo CL deC, BallasSK. Menopause in Brazilian women with sickle cell anemia with and without hydroxyurea therapy. Hematology Transfus Cell Ther, 2020; 43(3):386–388; doi: 10.1016/j.htct.2020.06.009
19.
AskewMA, SmaldoneAM, GoldMA, et al.Pediatric hematology providers' contraceptive practices for female adolescents and young adults with sickle cell disease: A national survey. Pediatr Blood Cancer, 2022:e29877; doi: 10.1002/pbc.29877
20.
KanterJ, HeathLE, KnorrJ, et al.Novel findings from the multinational DOVE study on geographic and age-related differences in pain perception and analgesic usage in children with sickle cell anaemia. Brit J Haematol, 2019; 184(6):1058–1061; doi: 10.1111/bjh.15250
21.
StrunkC, TartaglioneI, PicconeCM, et al.Global geographic differences in healthcare utilization for sickle cell disease pain crises in the CASiRe cohort. Blood Cells Mol Dis, 2021; 92:102612; doi: 10.1016/j.bcmd.2021.102612
22.
Knight-MaddenJ, Barton-GoodenA. Contraceptive usage among Jamaican women with sickle cell disease. Contraception, 2009; 80(5):474–478; doi: 10.1016/j.contraception.2009.05.121
23.
CarvalhoNS, BragaJP, BarbieriM, et al.Contraceptive practices in women with sickle-cell disease. J Obstet Gynaecol, 2017; 37(1):74–77; doi: 10.1080/01443615.2016.1225023
24.
EissaAA, TuckSM, RantellK, et al.Trends in family planning and counselling for women with sickle cell disease in the UK over two decades. J Fam Plann Reprod Health Care, 2015; 41(2):96–101; doi: 10.1136/jfprhc-2013-100763
25.
PeckerLH, HussainS, LanzkronS, et al.Women with sickle cell disease report low knowledge and use of long-acting reversible contraception. J Natl Med Assoc, 2021; 113(5):552–559; doi: 10.1016/j.jnma.2021.05.005
26.
RoeAH, LangB, McAllisterA, et al.Contraceptive use, and preferences among females with sickle cell disease. Contraception, 2022; 105:42–45; doi: 10.1016/j.contraception.2021.08.009
27.
KeoghSC, OtupiriE, CastilloPW, et al.Hormonal contraceptive use in Ghana: The role of method attributes and side effects in method choice and continuation. Contraception, 2021; 104(3):235–245; doi: 10.1016/j.contraception.2021.05.004
28.
de AboodM, de CastilloZ, GuerreroF, et al.Effect of Depo-Provera or Microgynon on the painful crises of sickle cell anemia patients. Contraception, 1997; 56(5):313–316.
29.
ManchikantiA, GrimesDA, LopezLM, et al.Steroid hormones for contraception in women with sickle cell disease. Gomez AM, ed. Cochrane Database Syst Rev, 2007;(2):CD006261; doi: 10.1002/14651858.cd006261.pub2
30.
OgunsileFJ, NaikR, LanzkronS. Overcoming challenges of venous thromboembolism in sickle cell disease treatment. Expert Rev Hematol, 2019; 12(3):173–182; doi: 10.1080/17474086.2019.1583554
31.
VliegAvH, HelmerhorstFM, RosendaalFR. The risk of deep venous thrombosis associated with injectable depot–medroxyprogesterone acetate contraceptives or a levonorgestrel intrauterine device. Arterioscler Thromb Vasc Biol, 2010; 30(11):2297–2300; doi: 10.1161/atvbaha.110.211482
32.
NHLBI Conference Proceedings. “Reproductive Health in Women with Sickle Cell Disease: From Gaps to Solutions.”. 2023. Available from: https://www.nhlbi.nih.gov/events/2023/reproductive-health-individuals-sickle-cell-disease-gaps-solutions [Last accessed: July18, 2023].
33.
DayME, StimpsonSJ, RodeghierM, et al.Contraceptive methods and the impact of menstruation on daily functioning in women with sickle cell disease. South Med J, 2019; 112(3):174–179; doi: 10.14423/smj.0000000000000949
34.
BuitingHM, OlthuisG. Importance of quality-of-life measurement throughout the disease course. JAMA Netw Open, 2020; 3(3):e200388; doi: 10.1001/jamanetworkopen.2020.0388
35.
OppongSA, AsareEV, OlayemiE, et al.Multidisciplinary care results in similar maternal and perinatal mortality rates for women with and without SCD in a low-resource setting. Am J Hematol, 2019; 94(2):223–230; doi: 10.1002/ajh.25356
36.
PeckerLH, Oteng-NtimE, NeroA, et al.Expecting more: the case for incorporating fertility services into comprehensive sickle cell disease care. Lancet Haematol, 2022; 10(3):e225–e234; doi: 10.1016/s2352-3026(22)00353-2
37.
ZiaA, LauM, JourneycakeJ, et al.Developing a multidisciplinary Young Women's Blood Disorders Program: a single-centre approach with guidance for other centres. Haemophilia, 2016; 22(2):199–207; doi: 10.1111/hae.12836
38.
RoeAH, MerjanehL, OxmanR, et al.Gynecologic health care for females with cystic fibrosis. J Clin Transl Endocrinol, 2021; 26:100277; doi: 10.1016/j.jcte.2021.100277
